Aerovate Therapeutics Inc
NASDAQ:AVTE
Operating Margin
Aerovate Therapeutics Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Aerovate Therapeutics Inc
NASDAQ:AVTE
|
75.7m USD | N/A | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
370.1B USD |
31%
|
|
| US |
U
|
US BioTec Inc
OTC:USBC
|
156.3B USD | N/A | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
159.1B USD |
31%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
144.2B USD |
38%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
101.9B USD |
39%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
107.5B AUD |
26%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
63.6B USD |
29%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
61.2B USD |
-7%
|
Aerovate Therapeutics Inc
Glance View
Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. The company is headquartered in Boston, Massachusetts and currently employs 16 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The firm's lead program is a drug that addresses the core disease processes of pulmonary arterial hypertension (PAH). AV-101 is an inhaled dry powder formulation of imatinib that conveniently delivers the medicine directly to the diseased lung tissues while reducing systemic adverse effects. AV-101's anti-proliferative mechanism is distinguished from vasodilatory therapies and is poised to make a meaningful difference in the lives of PAH patients. The firm has completed a Phase I trial in the United States of AV-101 in 82 healthy adults. In its Phase I trial, there were no adverse events associated with AV-101. The company anticipates initiating a double-blinded, placebo-controlled, randomized Phase II b/III trial of AV-101.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Aerovate Therapeutics Inc's most recent financial statements, the company has Operating Margin of 0%.
You don't have any saved screeners yet